NASDAQ: MSLESatellos Bioscience Inc Stock
$6.50+0.30 (+4.84%)
Updated Apr 10, 2026
MSLE Price
$6.50
Fair Value Price
$4.20
Market Cap
$100.48M
52 Week Low
$5.50
52 Week High
$13.40
P/E
-3.82x
P/B
3.62x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$24.87M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.15
Operating Cash Flow
-$24M
Beta
2.07
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MSLE Overview
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MSLE's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MSLE
Ranked#409 of 460
Ranked#409 of 460
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.76 | A | |
| $5.85 | A | |
| $194.20 | A |
Be the first to know about important MSLE news, forecast changes, insider trades & much more!
MSLE News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MSLE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MSLE ($6.50) is overvalued by 54.75% relative to our estimate of its Fair Value price of $4.20 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MSLE ($6.50) is not significantly undervalued (54.75%) relative to our estimate of its Fair Value price of $4.20 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MSLE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MSLE due diligence checks available for Premium users.
Valuation
MSLE fair value
Fair Value of MSLE stock based on Discounted Cash Flow (DCF)
Price
$6.50
Fair Value
$4.20
Overvalued by
54.75%
MSLE ($6.50) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MSLE ($6.50) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MSLE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MSLE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.82x
Industry
27.82x
Market
29.91x
MSLE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.62x
Industry
4.82x
MSLE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MSLE's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
MSLE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$31.9M
Liabilities
$4.1M
Debt to equity
0.15
MSLE's short-term assets ($31.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MSLE's short-term assets ($31.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MSLE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
MSLE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MSLE vs Biotech Stocks
Satellos Bioscience Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.